IS8064A - Notkun ísókínólínafleiða til að meðhöndla krabbamein og sjúkdóma sem tengjast MAP kínasa - Google Patents

Notkun ísókínólínafleiða til að meðhöndla krabbamein og sjúkdóma sem tengjast MAP kínasa

Info

Publication number
IS8064A
IS8064A IS8064A IS8064A IS8064A IS 8064 A IS8064 A IS 8064A IS 8064 A IS8064 A IS 8064A IS 8064 A IS8064 A IS 8064A IS 8064 A IS8064 A IS 8064A
Authority
IS
Iceland
Prior art keywords
map kinase
diseases associated
treat cancer
isoquinoline derivatives
treatment
Prior art date
Application number
IS8064A
Other languages
English (en)
Icelandic (is)
Inventor
Bryant Batt David
Bold Guido
Kim Sunkyu
Michael Ramsey Timothy
Lloyd Sabio Michael
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of IS8064A publication Critical patent/IS8064A/is

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035Isoindoles, e.g. phthalimide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/472Non-condensed isoquinolines, e.g. papaverine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/472Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
IS8064A 2003-03-11 2005-10-10 Notkun ísókínólínafleiða til að meðhöndla krabbamein og sjúkdóma sem tengjast MAP kínasa IS8064A (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45362403P 2003-03-11 2003-03-11
PCT/EP2004/002460 WO2004080464A1 (en) 2003-03-11 2004-03-10 Use of isoquinoline derivatives for treating cancer and map kinase related diseases

Publications (1)

Publication Number Publication Date
IS8064A true IS8064A (is) 2005-10-10

Family

ID=32990797

Family Applications (1)

Application Number Title Priority Date Filing Date
IS8064A IS8064A (is) 2003-03-11 2005-10-10 Notkun ísókínólínafleiða til að meðhöndla krabbamein og sjúkdóma sem tengjast MAP kínasa

Country Status (22)

Country Link
EP (1) EP1603566B1 (https=)
JP (1) JP2006519807A (https=)
KR (1) KR20050108383A (https=)
CN (1) CN1758910A (https=)
AT (1) ATE421324T1 (https=)
AU (1) AU2004218914A1 (https=)
BR (1) BRPI0408257A (https=)
CA (1) CA2518530A1 (https=)
DE (1) DE602004019193D1 (https=)
ES (1) ES2318276T3 (https=)
HR (1) HRP20050788A2 (https=)
IS (1) IS8064A (https=)
MA (1) MA27724A1 (https=)
MX (1) MXPA05009687A (https=)
NO (1) NO20054647L (https=)
PL (1) PL1603566T3 (https=)
PT (1) PT1603566E (https=)
RU (1) RU2325159C2 (https=)
TN (1) TNSN05223A1 (https=)
TW (1) TW200501955A (https=)
WO (1) WO2004080464A1 (https=)
ZA (1) ZA200506571B (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2526285A1 (en) 2003-05-15 2004-12-23 Arqule, Inc. Inhibitors of p38 and methods of using the same
AR045944A1 (es) * 2003-09-24 2005-11-16 Novartis Ag Derivados de isoquinolina 1.4-disustituidas
WO2006010082A1 (en) 2004-07-08 2006-01-26 Arqule, Inc. 1,4-disubstituted naphtalenes as inhibitors of p38 map kinase
EP2258704A1 (en) 2004-10-19 2010-12-08 ArQule, Inc. Synthesis of imidazooxazole and imidazothiazole inhibitors of p38 map kinase
EP1863491A1 (en) * 2005-02-25 2007-12-12 Novartis AG Pharmaceutical combination of bcr-abl and raf inhibitors
RS52241B (sr) * 2005-07-26 2012-10-31 Sanofi Derivati cikloheksilamin izohinolona kao inhibitori rho-kinaze
EP2046753A2 (en) 2006-07-06 2009-04-15 Brystol-Myers Squibb Company Pyridone/hydroxypyridine 11-beta hydroxysteroid dehydrogenase type i inhibitors
JP2009077712A (ja) * 2007-09-11 2009-04-16 F Hoffmann La Roche Ag B−Rafキナーゼ阻害剤に対する感受性についての診断試験
US8926561B2 (en) 2009-07-30 2015-01-06 Tandem Diabetes Care, Inc. Infusion pump system with disposable cartridge having pressure venting and pressure feedback
BR112012022801B8 (pt) * 2010-03-09 2019-10-29 Dana Farber Cancer Inst Inc método de identificar um indivíduo que tem câncer que é provável beneficiar-se do tratamento com uma terapia de combinação com um inibidor de raf e um segundo inibidor e uso de um inibidor de raf e um segundo inibidor para a fabricação de um medicamento para tratar câncer
US9056855B2 (en) * 2010-10-28 2015-06-16 Viamet Pharmaceuticals, Inc. Metalloenzyme inhibitor compounds
CN103435430B (zh) * 2013-08-08 2015-02-18 四川大学 一种还原酰胺类化合物的方法
KR102119943B1 (ko) 2018-05-23 2020-06-05 주식회사 포스코 시편배치유닛 및 이를 포함하는 도장밀착성 실험장치
CA3104808A1 (en) * 2018-07-02 2020-01-09 Ecole Polytechnique Federale De Lausanne (Epfl) Lactate enhancing compounds and uses thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW544448B (en) * 1997-07-11 2003-08-01 Novartis Ag Pyridine derivatives
PT1107964E (pt) * 1998-08-11 2010-06-11 Novartis Ag Derivados de isoquinolina com actividade inibidora da angiogénese
DOP2000000070A (es) * 1999-09-28 2002-02-28 Bayer Healthcare Llc Piridinas y piridacinas sustituidas con actividad de inhibición de angiogénesis
PT1254138E (pt) * 2000-02-09 2005-09-30 Novartis Ag Derivados de piridina que inibem a angiogenese e/ou o receptor de tirosina cinase do vegf
US20030078271A1 (en) * 2001-01-31 2003-04-24 Blackburn Thomas P. Use of GAL3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods
ATE497603T1 (de) * 2001-03-02 2011-02-15 Gpc Biotech Ag Drei-hybrid-assaysystem
WO2003059354A2 (en) * 2001-12-21 2003-07-24 Bayer Pharmaceuticals Corporation Anti-angiogenesis combination therapies comprising pyridazine or pyridine derivatives
US7220775B2 (en) * 2002-08-07 2007-05-22 H. Lundbeck A/S Compound useful for the treatment of neuropathic pain

Also Published As

Publication number Publication date
ATE421324T1 (de) 2009-02-15
RU2005131168A (ru) 2006-05-27
EP1603566B1 (en) 2009-01-21
TNSN05223A1 (en) 2007-06-11
BRPI0408257A (pt) 2006-03-07
TW200501955A (en) 2005-01-16
ZA200506571B (en) 2006-07-26
EP1603566A1 (en) 2005-12-14
JP2006519807A (ja) 2006-08-31
AU2004218914A1 (en) 2004-09-23
PT1603566E (pt) 2009-04-27
DE602004019193D1 (de) 2009-03-12
KR20050108383A (ko) 2005-11-16
NO20054647L (no) 2005-12-09
PL1603566T3 (pl) 2009-07-31
MXPA05009687A (es) 2005-10-20
NO20054647D0 (no) 2005-10-10
WO2004080464A1 (en) 2004-09-23
RU2325159C2 (ru) 2008-05-27
ES2318276T3 (es) 2009-05-01
CA2518530A1 (en) 2004-09-23
CN1758910A (zh) 2006-04-12
HRP20050788A2 (en) 2006-12-31
MA27724A1 (fr) 2006-01-02

Similar Documents

Publication Publication Date Title
IS8064A (is) Notkun ísókínólínafleiða til að meðhöndla krabbamein og sjúkdóma sem tengjast MAP kínasa
TNSN05045A1 (en) Indole or benzimidazole derivatives for modulating ikappab kinase
MXPA05009595A (es) Compuestos 7-amino-isoindolilo y sus usos farmaceuticos.
DE60206911D1 (de) Imidazol-2-carbonsäureamid derivate als raf-kinase-inhibitoren
TNSN05044A1 (en) Use of ikappab kinase inhibitors for the treatment of pain
DE60220290D1 (de) Pyridinderivate als inhibitoren der raf-kinase
ATE448232T1 (de) Substituierte heterozyklen
MX2009009574A (es) Tratamiento de melanoma.
PA8599701A1 (es) Formas de dosificacion y procedimientos de tratamiento que usan inhibidores del vegfr
PT1390371E (pt) Oxazolo- e furopirimidinas e sua utilizacao em medicamentos contra tumores
NO20054494L (no) Peptidvektorer
NO20055741D0 (no) Nye kjemiske forbindelser
EA200501310A1 (ru) Производные бензолсульфонамидов, способ их получения и их применение для лечения боли
ATE311389T1 (de) Wirkstoffvorläufer von imidazopyridin-derivaten
NO20050640L (no) Rutenium anticancer komplekser
GB0121494D0 (en) Compounds
DE60131968D1 (de) PYRANOÄ2,3-cÜIMIDAZOÄ1,2-aÜPYRIDIN-DERIVATE ZUR BEHANDLUNG VON GASTROINTESTINALEN ERKRANKUNGEN
ATE406375T1 (de) Antitumor wirksame 2-substituierte d-homoestra-1, 3,5(10)-trien-3-yl sulfamate
NO20055650L (no) Ruteinum (II)-komplekser for behandling av tumorer
ATE423780T1 (de) Makrozyclen zur behandlung von krebserkrankungen
ATE328883T1 (de) Imidazopyridin-8-one
TH77920A (th) การใช้อิโพธิโลนในการรักษาการย้ายที่ของโรคมาที่กระดูก